PS: Not available yet but assume soon (for lots of money!)

Vyalev (foscarbidopa and foslevodopa; AbbVie, North Chicago, IL) has been granted Food and Drug Administration (FDA) approval for the treatment of motor fluctuations in adults with advanced Parkinson disease (PD). Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy to receive FDA approval for the treatment of motor fluctuations in this population. Treatment with Vyalev is initiated in a health care provider office, and the medication is delivered by a wearable pump for up to 24 hours per day. This method of administration enables patients to manage treatment at home without traveling to receive their infusion.

https://practicalneurology.com/news/fda-approves-first-subcutaneous-24-hour-continuous-levodopa-based-infusion-for-the-treatment-of-advanced-parkinson-disease